Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.
Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.
复制标题
重组人促红细胞生成素治疗早产儿贫血：安慰剂对照试点研究的结果。
DOI：
10.1016/s0022-3476(05)82217-6
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Phibbs,RH
中科院分区：
文献类型：
--
作者：
Shannon,KM;Mentzer,WC;Abels,RI;Freeman,P;Newton,N;Thompson,D;Sniderman,S;Ballard,R;Phibbs,RH
实验和临床数据表明，红细胞生成不足是婴儿获得这种贫血的重要原因，并提示重组人红细胞生成素（r-HuEPO）可能用于治疗或预防。（出生体重≤1250 gm）极有可能因早产儿贫血而需要红细胞输注的患者接受6周的静脉注射r-HuEPO治疗（剂量为100单位/kg，每周两次）或安慰剂。在治疗期间和治疗后6个月随访血液学测量、输血要求和生长情况。治疗组和对照组婴儿在体重、红细胞压积、网织红细胞绝对计数、计算的红细胞质量或生长速率方面没有差异。然而，网织红细胞计数增加较早的患者给予重组人促红细胞生成素。EPO组的10名婴儿中有6名，对照组的10名婴儿中有8名，在治疗期间接受了至少一次红细胞输注。对于所有婴儿，用于实验室检查的血液采样量强烈预测输注的红细胞压积体积（r=0.890;p=0.0001）。在9名被取出<20 ml浓缩红细胞进行实验室检查的婴儿中，4名给予r-HuEPO的婴儿没有接受输血，而5名被分配到安慰剂组的婴儿中有3名接受了输血。无毒性作用归因于r-HuEPO，在治疗过程中，白细胞或血小板计数没有发生显着变化。在两个研究组中，网织红细胞计数与同时血小板计数相关，与中性粒细胞绝对计数呈负相关。我们的结论是，r-HuEPO管理是安全和可行的剂量研究。利用更高剂量的r-HuEPO和更多患者进行额外的对照试验是合理的。
Experimental and clinical data implicate inadequate erythropoletin production as an important reason that infants acquire this anemia and suggest that recombinant human erythropoletin (r-HuEPO) might be used to treat or prevent it. We therefore randomly assigned 20 small premature infants (birth weight ≤1250 gm) who were highly likely to require erythrocyte transfusions for anemia of prematurity to receive 6 weeks of treatment with either intravenously administered r-HuEPO (at a dose of 100 units/kg twice each week) or a placebo. Hematologic measurements, transfusion requirements, and growth were followed during therapy and for 6 months thereafter. Treated (EPO) and control babies did not differ with respect to weight, hematocrit, overall mean absolute reticulocyte count, calculated erythrocyte mass, or rate of growth. However, reticulocyte counts increased earlier in patients given r-HuEPO. Six of ten babies in the EPO group, and 8 of 10 assigned to the control group, received at least one erythrocyte transfusion during treatment. For all infants the amount of blood sampled for laboratory tests was strongly predictive of the volume of packed erythrocytes transfused (r=0.890;p=0.0001). Of nine infants who had <20 ml packed erythrocytes removed for laboratory tests, none of four given r-HuEPO received a transfusion, whereas three of five infants assigned to the placebo group received one. No toxic effects were attributable to r-HuEPO, and no significant changes in leukocyte or platelet counts occurred during treatment. Reticulocyte counts were correlated with simultaneous platelet counts and were inversely related to absolute neutrophil counts in both study groups. We conclude that r-HuEPO administration is safe and feasible at the dose studied. Additional controlled trials utilizing higher doses of r-HuEPO and larger numbers of patients are justified.
登录
查看更多内容
使用荧光激活流式细胞术计数网织红细胞。
DOI：
--
发表时间：
1988
期刊：
Pathology and Immunopathology Research
影响因子：
--
作者：
L. Corash;M. Rheinschmidt;S. Lieu;P. Meers;E. Brew
通讯作者：
E. Brew
DOI：
10.1016/s0022-3476(05)82670-8
发表时间：
1990
期刊：
The Journal of pediatrics
影响因子：
--
作者：
Mark S. Brown;Edward R. Berman;Dennis Luckey
通讯作者：
Dennis Luckey
早产儿贫血：进展与前景。
DOI：
--
发表时间：
1990
期刊：
American Journal Of Pediatric Hematology/Oncology
影响因子：
--
作者：
K. Shannon
通讯作者：
K. Shannon
影响因子：
5.1
作者：
HALPERIN, DS;WACKER, P;WYSS, M
通讯作者：
WYSS, M
人类造血克隆中促红细胞生成素下调中性粒细胞的产生。
影响因子：
20.3
作者：
R. Christensen;JM Koenig;D. Viskochil;G. Rothstein
通讯作者：
G. Rothstein